Phase II open, single-center, pilot clinical trial to assess the pharmacokinetics, safety and tolerability, after the conversion of an immunosuppressive regimen with Prograf to prolonged release tacrolimus (Advagraf) in stable lung transplant patients [ENSAYO CLÍNICO DE FASE II, ABIERTO, UNICÉNTRICO, PILOTO PARA EVALUAR LAS CARACTERÍSTICAS FARMACOCINÉTICAS, SEGURIDAD Y TOLERABILIDAD, TRAS LA CONVERSIÓN DE UN RÉGIMEN INMUNOSUPRESOR CON PROGRAF A TACROLIMUS DE LIBERACIÓN PROLONGADA (ADVAGRAF) EN PACIENTES CON TRASPLANTE PULMONAR ESTABLE]

Trial Profile

Phase II open, single-center, pilot clinical trial to assess the pharmacokinetics, safety and tolerability, after the conversion of an immunosuppressive regimen with Prograf to prolonged release tacrolimus (Advagraf) in stable lung transplant patients [ENSAYO CLÍNICO DE FASE II, ABIERTO, UNICÉNTRICO, PILOTO PARA EVALUAR LAS CARACTERÍSTICAS FARMACOCINÉTICAS, SEGURIDAD Y TOLERABILIDAD, TRAS LA CONVERSIÓN DE UN RÉGIMEN INMUNOSUPRESOR CON PROGRAF A TACROLIMUS DE LIBERACIÓN PROLONGADA (ADVAGRAF) EN PACIENTES CON TRASPLANTE PULMONAR ESTABLE]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2011

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Lung transplant rejection
  • Focus Pharmacokinetics
  • Most Recent Events

    • 14 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top